HCPCS Level II · Drugs administered other than oral method
J2267Injection, mirikizumab-mrkz, 1 mg
✓ Active
Source: CMS HCPCS quarterly update, October 2026. Page updated September 29, 2026.
About J2267
J2267 is an HCPCS Level II code in the J series (drugs administered other than oral method), describing injection, mirikizumab-mrkz, 1 mg.
It was added to HCPCS effective 07/01/2024.
Its Medicare coverage code is "C", meaning coverage is left to the Medicare contractor's judgment.
Details
- Short description
- Inj, mirikizumab-mrkz, 1 mg
- Date added
- 07/01/2024
- Action effective
- 07/01/2024
- BETOS
- O1E
Related J22xx codes
- J2210Injection, methylergonovine maleate, up to 0.2 mg
- J2212Injection, methylnaltrexone, 0.1 mg
- J2246Injection, micafungin in sodium (baxter), not therapeutically equivalent to j2248, 1 mg
- J2247Injection, micafungin sodium (par pharm) not thereapeutically equivalent to j2248, 1 mg
- J2248Injection, micafungin sodium, 1 mg
- J2249Injection, remimazolam, 1 mg
- J2250Injection, midazolam hydrochloride, per 1 mg
- J2251Injection, midazolam in 0.9% sodium chloride, intravenous, not therapeutically equivalent to j2250, 1 mg
- J2252Injection, midazolam in 0.8% sodium chloride, intravenous, not therapeutically equivalent to j2250, 1 mg
- J2253Injection, midazolam (seizalam), 1 mg
- J2260Injection, milrinone lactate, 5 mg
- J2265Injection, minocycline hydrochloride, 1 mg
Common questions about J2267
Is HCPCS J2267 still valid?
- Yes. J2267 is active in the CMS October 2026 HCPCS file.
Does Medicare cover J2267?
- Its coverage code is "C": coverage is left to the Medicare contractor's judgment. Check the local coverage determination for your region.